The news just keeps getting worse for CEO Martin Shkreli. San Diego-based Imprimis Pharmaceuticals, Inc. announced this week that it will be producing an alternative to Daraprim.
The price? $1 per tablet. That’s $749 less than Shkreli’s price. Shkreli is the owner and CEO of Turing Pharmaceuticals.
He was named “the most hated man in America” by several media outlets last month after he raised the price of Daraprim, a drug used by some HIV patients, from $13.50 to $750 per tablet.
“While we respect Turing’s right to charge patients and insurance companies whatever it believes is appropriate, there may be more cost-effective compounded options for medications, such as Daraprim,” Imprimis CEO Mark L. Baum said in a press release. The press release added that the new drug won’t be exactly the same as Daraprim… it will actually be better: Daraprim’s active ingredient is pyrimethamine, which has been available since 1953 for the treatment of parasitic diseases … Imprimis’ alternative also contains pyrimethamine as well as leucovorin, which the company said helps to reverse pyrimethamine’s negative effects on bone marrow.
“Today, some drug prices are simply out of control and we believe we may be able to help control costs by offering compounded alternatives to several sole source legacy generic drugs,” Baum said. “We are here to serve our patients and their physicians. We believe that when we do a great job serving our customers, our shareholders will also benefit.” So far, Shkreli’s only response to his new competitor has been in a statement to U.S. Uncut, in which he simply said: “LOL.”